{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:32:07Z","timestamp":1785861127965,"version":"3.56.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1097\/01.fjc.0000211787.30034.0a","type":"journal-article","created":{"date-parts":[[2006,6,29]],"date-time":"2006-06-29T08:05:40Z","timestamp":1151568340000},"page":"758-763","source":"Crossref","is-referenced-by-count":11,"title":["Effects of Fenofibrate on C-reactive Protein Levels in Hypertriglyceridemic Patients"],"prefix":"10.1097","volume":"47","author":[{"given":"Chee","family":"Jeong Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210208","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"R2-6-20210208","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/01.CIR.104.3.365","article-title":"Current concepts of the pathogenesis of the acute coronary syndromes","volume":"104","author":"Libby","year":"2001","journal-title":"Circulation"},{"key":"R3-6-20210208","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/oxfordjournals.aje.a008963","article-title":"Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial","volume":"144","author":"Kuller","year":"1996","journal-title":"Am J Epidemiol"},{"key":"R4-6-20210208","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.CIR.0000053730.47739.3C","article-title":"Clinical application of C-reactive protein for cardiovascular disease detection and prevention","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"R5-6-20210208","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1345\/aph.1D203","article-title":"Role of C-reactive protein in cardiovascular disease","volume":"38","author":"Backes","year":"2004","journal-title":"Ann Pharmacother"},{"key":"R6-6-20210208","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/31701","article-title":"Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators","volume":"393","author":"Staels","year":"1998","journal-title":"Nature"},{"key":"R7-6-20210208","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1055\/s-0037-1613861","article-title":"Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin alone and in combination treatment","volume":"83","author":"Cortellaro","year":"2000","journal-title":"Thromb Haemost"},{"key":"R8-6-20210208","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0008-6363(01)00382-0","article-title":"Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial\u2014FAT)","volume":"52","author":"Malik","year":"2001","journal-title":"Cardiovasc Res"},{"key":"R9-6-20210208","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0021-9150(01)00708-0","article-title":"Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia","volume":"162","author":"Gomez-Gerique","year":"2002","journal-title":"Atherosclerosis"},{"key":"R10-6-20210208","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0021-9150(03)00296-X","article-title":"Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles","volume":"170","author":"Wang","year":"2003","journal-title":"Atherosclerosis"},{"key":"R11-6-20210208","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1161\/01.ATV.0000062990.62034.64","article-title":"Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome","volume":"23","author":"Despres","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R12-6-20210208","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0002-9343(01)01123-8","article-title":"Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial","volume":"112","author":"Jonkers","year":"2002","journal-title":"Am J Med"},{"key":"R13-6-20210208","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/107424840400900i105","article-title":"Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values","volume":"9","author":"Tsimihodimos","year":"2004","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R14-6-20210208","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.atherosclerosis.2004.01.033","article-title":"Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis","volume":"174","author":"Koh","year":"2004","journal-title":"Atherosclerosis"},{"key":"R15-6-20210208","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cccn.2005.01.023","article-title":"Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia","volume":"356","author":"Ye","year":"2005","journal-title":"Clin Chim Acta"},{"key":"R16-6-20210208","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.100.3.230","article-title":"Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators","volume":"100","author":"Ridker","year":"1999","journal-title":"Circulation"},{"key":"R17-6-20210208","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.103.15.1933","article-title":"Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels","volume":"103","author":"Jialal","year":"2001","journal-title":"Circulation"},{"key":"R18-6-20210208","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/0021-9150(94)05378-V","article-title":"Efficacy and tolerance of 200\u2009mg micronised fenofibrate administered over a six month period in hyperlipidemic patients: an open Belgian multicenter study","volume":"110","author":"Kornitzer","year":"1994","journal-title":"Atherosclerosis"},{"key":"R19-6-20210208","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1001\/jama.1989.03430220077034","article-title":"The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study","volume":"262","author":"Leaf","year":"1989","journal-title":"JAMA"},{"key":"R20-6-20210208","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"R21-6-20210208","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.2337\/diacare.22.12.1971","article-title":"Body mass index, diabetes, and C-reactive protein among U.S. adults","volume":"22","author":"Ford","year":"1999","journal-title":"Diabetes Care"},{"key":"R22-6-20210208","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1161\/01.ATV.19.8.1986","article-title":"Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women","volume":"19","author":"Hak","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R23-6-20210208","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1161\/01.ATV.21.6.968","article-title":"Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women","volume":"21","author":"Heilbronn","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R24-6-20210208","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1161\/hc0502.103331","article-title":"Weight loss reduces C-reactive protein levels in obese postmenopausal women","volume":"105","author":"Tchernof","year":"2002","journal-title":"Circulation"},{"key":"R25-6-20210208","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0002-9149(02)03110-7","article-title":"Role of C-reactive protein in the assessment of cardiovascular risk","volume":"91","author":"Jialal","year":"2003","journal-title":"Am J Cardiol"}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000637-200604000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:39:10Z","timestamp":1785857950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005344-200606000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.fjc.0000211787.30034.0a","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}